Dr. Sanjiv Agarwala brings up the potential issue of toxicity that may arise in combining immunotherapies and argues that the benefits outweigh the risks.
Dr. Sanjiv Agarwala discusses the pros and cons of using Pembrolizumab over anti-CTLA4 antibody therapy.
Dr. Sanjiv Agarwala analyzes anti-PD-1 and anti-PD-L1 therapies in terms what they do and their unique toxicities and response patterns.
Dr. Sanjiv Agarwala addresses the possibility of updating indications for Nivolumab and Pembrolizumab in the therapeutic arena.
Dr. Sanjiv Agarwala examines the benefits of anti-PD-1 therapy vs. anti-CTLA4 therapy and how these therapies may be used on their own and in combination with each other in the future.
Dr. Sanjiv Agarwala gives an overview of the roles dermatologists and medical oncologists play and expands on how and why they need to work together to improve cancer care.
Dr. Sanjiv Agarwala discusses when and why to utilize local regional therapy versus surgery for melanoma.
Dr. Sanjiv Agarwala talks about the importance of personalizing melanoma care, focusing on where the industry currently stands and what’s in store for the future of targeted therapies and immunotherapies.
Dr. Sanjiv Agarwala identifies the newest developments in treatments for melanoma, cutaneous T-cell lymphoma, Merkel cell carcinoma, squamous-cell carcinoma, and invasive-cell carcinoma.
In the first WCMC clinical commentary entitled, The Role of Hedgehog Pathway Inhibition in Advanced Basal Cell Carcinoma, Dirk Schadendorf, MD; Nicole Basset-Seguin, MD, PhD; Aleksander Sekulic, MD, PhD discuss how the hedgehog pathway plays a critical role in developing basal cell carcinoma and how inhibitors are providing new strategies [ Read More ]